Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Operations: 2011-2025

Historic Cash from Operations for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $1.5 million.

  • Fennec Pharmaceuticals' Cash from Operations rose 167.68% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 133.84%. This contributed to the annual value of $27.0 million for FY2024, which is 257.38% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Cash from Operations of $1.5 million as of Q3 2025, which was up 140.50% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Cash from Operations ranged from a high of $39.0 million in Q1 2024 and a low of -$8.4 million during Q2 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$3.7 million (2025), whereas its average is $302,364.
  • Within the past 5 years, the most significant YoY rise in Fennec Pharmaceuticals' Cash from Operations was 800.14% (2024), while the steepest drop was 112.54% (2024).
  • Fennec Pharmaceuticals' Cash from Operations (Quarterly) stood at -$3.0 million in 2021, then rose by 23.41% to -$6.8 million in 2022, then rose by 28.55% to -$4.9 million in 2023, then spiked by 69.67% to -$1.5 million in 2024, then skyrocketed by 167.68% to $1.5 million in 2025.
  • Its Cash from Operations stands at $1.5 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$4.3 million for Q1 2025.